Gregg Gilbert

Why This Bristol-Myers Squibb Stock Analyst Is Turning Bullish On The Pharma Company's Pipeline

How Valeant Finally Won Over A Longtime Bear

Analyst Eats 'Some Humble Pie,' Says Teva Needs To Deliver On Greater Visibility In Coming Months

How Valeant Finally Won Over A Longtime Bear

Analyst Eats 'Some Humble Pie,' Says Teva Needs To Deliver On Greater Visibility In Coming Months

Zoetis Investors May Need Patience To See Bull Thesis Play Out

Akorn Take-Out Chatter Supported By Trend Of Consolidation In Generic Drug Companies

Zoetis Investors May Need Patience To See Bull Thesis Play Out

Akorn Take-Out Chatter Supported By Trend Of Consolidation In Generic Drug Companies

Valeant's Refinancing Explained

More Pros Than Cons Investing In Impax Right Now

Gregg Gilbert Recent News

Does Reward Potential Still Outweigh The Risk In Akorn Shares?

Deutsche Bank Casts Doubt On Pfizer's Rumored Takeover Approach To Bristol-Myers

What The Copaxone Court Ruling Means For Teva Pharmaceuticals

Amid Exec Departure, Teva's 2017 Outlook Now More Important Than Ever

Deutsche Tweaking Its Mylan View Following CEO's Congressional Testimony

Recent Patent Ruling A Positive For Pfizer

Jazz Pharmaceuticals Remains A Buy At Deutsche Bank Post Q2 Report

Deutsche Thinks Perrigo's Lowered Expectations Are Beatable

Deutsche Analysts React To Bristol-Myers Clinical Trial Disappointment

Deutsche Downgrades Ligand As Risk/Reward Becomes Challenging

A Fairly Balanced Risk And Reward Scenario For Lannett; Deutsche Bank Initiates At Hold

Is Allergan Worth Over $300 Without Pfizer?

Deutsche Bank: Valeant Stock Could Be Worth $18, $30 Or $36

Deutsche Bank Suspends Valeant Rating, Says It Was 'Long Skeptical' Of Business Model

Jazz Pharma Falls After Q4 Sales Miss Street View

Eli Lilly Could Make A Lot More From Alzheimer's Drug Than Originally Thought

Here's Why Valeant Is Worrying Deutsche Bank And Morgan Stanley

Endo Bought Par In One Of Biggest Generics M&A Deals Ever: What The Street's Saying

How Teva Grows 'After The Cliff'

Roth Capital Analyst Squares Up Against Hedge Fund In Ligand Pharma

Deutsche Bank Cuts Ligand Pharma To Hold

Deutsche Bank Boosts Mylan's Price Target On This Scenario

Akorn Initiated At Deutsche Bank, Notes Impressive Drug Pipeline